Acadia Pharmaceuticals | ACAD - Loan Capital



Acadia Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.


Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 1.03B 956K Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Corcept Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 713.04M 67.88M Jun/2025
Eisai JPY 99.84B 9M Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Incyte USD 31.76M 883K Jun/2025
J&J USD 38.36B 7.7B Mar/2025
Moderna USD 32M 3M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
Pfizer USD 57.5B 137M Jun/2025
Prothena USD 0 0 Dec/2024
PTC Therapeutics USD 2.13B 1.85B Jun/2025
Sarepta Therapeutics USD 1.14B 1.17M Jun/2025
Ultragenyx Pharmaceutical USD 782.75M 782.75M Jun/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024